Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals
AssigneeThe Dow Chemical Company
InventorsGarry E. Kiefer, Jaime Simon
Life of this patent
Estimating the term…
Abstract
Complexes of bicyclopolyazamacrocyclophosphonic acid compounds with a metal ion, e.g. .sup.153 Sm, .sup.177 Lu, .sup.159 Gd, .sup.149 Pm, .sup.140 La, .sup.175 Yb, .sup.166 Ho, .sup.90 Y, .sup.47 Sc, .sup.186 Re, .sup.188 Re, .sup.142 Pr, .sup.99m Tc, .sup.67 Ga, .sup.68 Ga, .sup.105 Rh, .sup.97 Ru, .sup.111 In, .sup.113m In or .sup.115m In ion, are disclosed. The complexes can be covalently attached to a biologically active molecule, e.g. an antibody or antibody fragment, to form conjugates. The complexes and conjugates are useful as radiopharmaceutical agents for therapy and/or diagnostic purposes.
Claims10
A complex which comprises a bicyclopolyazamacrocyclophosphonic acid compound of the formula ##STR43## wherein:
- ##STR44## where:
- X and Y are independently H, OH, C.sub.1 -C.sub.3 alkyl or COOH;
- n is an integer of 1, 2 or 3;
- with the proviso that:
- when n is 2, then the sum of X and Y must equal two or more H;
- and when n is 3, then the sum of X and Y must equal three or more H;
- T is ##STR45## where:
- R.sup.1 is OH or C.sub.1 -C.sub.5 alkyl
- with the proviso that at least one T must be P(O)R.sup.1 OH where R.sup.1 is C.sub.1 -C.sub.5 alkyl;
- A is CH, N, C--Br, C--Cl, C--OR.sup.3, C--OR.sup.8, N.sup.+ --R.sup.5 X.sup.-, ##STR46## R.sup.3 is H, C.sub.1 -C.sub.5 alkyl, benzyl, or benzyl substituted with at least one R.sup.4 ;
- R.sup.4 is H, NO.sub.2, NH.sub.2, isothiocyanato, semicarbazido, thiosemicarbazido, maleimido, bromoacetamido or carboxyl;
- R.sup.5 is C.sub.1 -C.sub.16 alkyl, benzyl, or benzyl substituted with at least one R.sup.4 ;
- R.sup.8 is C.sub.1 -C.sub.16 alkylamino;
- X.sup.- is Cl.sup.-, Br.sup.-, I.sup.- or H.sub.3 CCO.sub.2.sup.- ;
- Q and Z independently are CH, N, N.sup.+ --R.sup.5 X.sup.-, C--CH.sub.2 --OR.sup.3 or C--C(O)--R.sup.6 ;
- R.sup.3 and R.sup.5 are defined as above;
- R.sup.6 is --O--(C.sub.1 -C.sub.3 alkyl), OH or NHR.sup.7 ;
- R.sup.7 is C.sub.1 -C.sub.5 alkyl or a biologically active material;
- X.sup.- is defined as above;
- or
- pharmaceutically-acceptable salts thereof;
- with the proviso that:
- a) when Q, A or Z is N or N.sup.+ --R.sup.5 X.sup.-, then the other two groups must be CH;
- b) when A is C--Br, C--Cl, C--OR.sup.3 or C--OR.sup.8, then both Q and Z must be CH;
- c) the sum of the R.sup.4, R.sup.7 and R.sup.8 terms, when present, may not exceed one;
- and
- d) only one of Q or Z can be C--C(O)--R.sup.6 and when one of Q or Z is C--C(O)--R.sup.6, then A must be CH;
- complexed with a metal ion of .sup.153 Sm, .sup.177 Lu, .sup.159 Gd, .sup.149 Pm, .sup.140 La, .sup.175 Yb, .sup.166 Ho, .sup.90 Y, .sup.47 Sc, .sup.186 Re, .sup.188 Re, .sup.142 Pr, .sup.99m Tc, .sup.67 Ga, .sup.68 Ga, .sup.105 Rh, .sup.97 Ru, .sup.111 In, .sup.113m In or .sup.115m In.
Dependencies are inferred from the claim text.